Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Alterity Therapeutics Ltd

ATHE ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.85

▲ +5.21%

Market Cap $83.72M · Vol 1.71K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$83.72M

Micro Cap

Div Yield

N/A

EPS Growth

-3,106.40%

YoY

RSI (14)

58.29

Momentum

Beta

0.22

vs Market

52W High

$5.89

17.66% below

52W Low

$2.70

79.63% above

Volume

1.71K

Avg 1.18K

P/B

0.04

Price-to-book

ROE

N/A

Return on equity

Free Float

99.23%

Public shares

Shariah Compliance8 STANDARDS

✗ Alterity Therapeutics Ltd (ATHE) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ATHE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.59%

-3.58%

+3.85%

+37.39%

YTD

+57.47%

-6.28%

+70.77%

-64.07%

Financials & Valuation

TTM · Annual

Total Revenue	$293.66K
Net Income	$-7,993,256.00
Revenue Growth (YoY)	+710.88%
Gross Margin	100.00%
Operating Margin	-4,404.40%
Net Profit Margin	-2,721.95%
ROE	N/A
ROA · ROIC	-37.03% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	3.02
P/B	0.04
P/FCF	N/A
EPS Growth	-3,106.40%
Outstanding Shares	217.77M

Technical Indicators

50-Day SMA	$4.77
200-Day SMA	$3.95
RSI (14)	58.29
Beta	0.22
52-Week High	$5.89
52-Week Low	$2.70

Volume Today	1.71K
Avg Daily Volume (30D)	1.18K
Relative Volume	1.45x
Volatility (10D)	57.34
Volatility (30D)	57.50
Free Float	99.23%

Analyst Consensus

BUY

Current Price $4.85

Mean Target $12.67

52W Low$2.70 52W High$5.89

Current

Target

$2.70 $5.89

Current Analyst target

+161.17% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SHP8H6

ISINUS02155X2053

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.